Pharmaceuticals, Biotechnology and Life Sciences
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior,…
WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…
Five-Year Financing with Favorable Terms that Significantly Reduce Interest RateSTOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.…
GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any…
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company’s own shares.…
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces…
Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditionsSupported by Health Moonshot Champions, including the…
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as…
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC)…